Predictor: Randomized phase II study of preoperative afatinib in untreated nonmetastatic head and neck squamous cell carcinoma patients (HNSCC) aiming at identifying predictive and pharmacodynamic biomarkers of efficacy.
Christophe Le Tourneau
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Gilles Dolivet
No relevant relationships to disclose
Olivier Capitain
No relevant relationships to disclose
Laurent Laccourreye
No relevant relationships to disclose
Jerome Fayette
No relevant relationships to disclose
Dominique De Raucourt
No relevant relationships to disclose
Frederic Peyrade
No relevant relationships to disclose
Olivier Malard
No relevant relationships to disclose
Frederic Rolland
No relevant relationships to disclose
Christine Orsini
No relevant relationships to disclose
Odette Mariani
No relevant relationships to disclose
Jerzy Klijanienko
No relevant relationships to disclose
Leanne de Koning
No relevant relationships to disclose
Ivan Bieche
No relevant relationships to disclose
Xavier Sastre
No relevant relationships to disclose
Nicolas Aide
No relevant relationships to disclose
Xavier Paoletti
No relevant relationships to disclose
Stéphane Temam
No relevant relationships to disclose